NEWS
Kalytera, Salzman licence agreement amended
2021-04-05 20:26 ET - Property Agreement
The TSX Venture Exchange has accepted for filing an amendment of licence agreement dated Feb. 17, 2021, between Salzman Group Inc., a Delaware corporation, Salzman Group Ltd., an Israeli corporation, and Salzman Group Pty. Ltd., an Australian corporation (collectively the Salzman Group), and Kalytera Therapeutics Inc., whereby the company may acquire a licence to develop and commercialize R-107 with a licensc fee of $1.2-million (U.S.) and the issuance of 130 million common shares of the company to the Salzman Group. Further considerations include a success fee of $2-million (U.S.) based on certain milestone and additional milestone payments in stages in the cash amount of $4.25-million (U.S.).
© 2021 Canjex Publishing Ltd. All rights reserved.